

UC San Diego

UC San Diego Previously Published Works

Title

Actigraphy- and Polysomnography-Measured Sleep Disturbances, Inflammation, and Mortality Among Older Men.

Permalink

<https://escholarship.org/uc/item/6sv2v9v7>

Journal

Psychosomatic medicine, 78(6)

ISSN

0033-3174

Authors

Smagula, Stephen F
Stone, Katie L
Redline, Susan
et al.

Publication Date

2016-07-01

DOI

10.1097/psy.0000000000000312

Supplemental Material

<https://escholarship.org/uc/item/6sv2v9v7#supplemental>

Peer reviewed

Table 3. Hazard ratio (95% CI) of mortality by sleep measures

	All cause (628 deaths)	CVD (217 deaths)	Cancer (171 deaths)	Non-cancer Non-CVD (240 deaths)
<u>AHI ≥30 vs. <30</u>				
Model 1: Crude model	1.06 (0.86-1.29)	1.38 (1.00-1.90)	0.89 (0.59-1.34)	0.90 (0.63-1.27)
Model 2a: Model 1 + MV	1.03 (0.84-1.27)	1.35 (0.98-1.88)	0.88 (0.58-1.33)	0.86 (0.60-1.24)
Model 2b: Model 1 + # high inflammatory markers	1.03 (0.84-1.26)	1.33 (0.97-1.84)	0.88 (0.59-1.33)	0.87 (0.61-1.24)
Model 3: Model 1 + MV* + # high inflammatory markers	1.03 (0.84-1.27)	1.34 (0.97-1.85)	0.87 (0.58-1.32)	0.87 (0.61-1.26)
<u>≥10% vs. <10% TST SaO₂<90%</u>				
Model 1: Crude model	1.28 (1.02-1.61)	1.24 (0.85-1.80)	1.30 (0.84-1.99)	1.32 (0.91-1.92)
Model 2a: Model 1 + MV	1.13 (0.90-1.43)	1.12 (0.77-1.64)	1.29 (0.83-2.00)	1.09 (0.74-1.60)
Model 2b: Model 1 + # high inflammatory markers	1.17 (0.93-1.46)	1.08 (0.74-1.58)	1.27 (0.83-1.96)	1.17 (0.80-1.70)
Model 3: Model 1 + MV* + # high inflammatory markers	1.07 (0.85-1.35)	1.02 (0.69-1.49)	1.27 (0.82-1.98)	1.00 (0.68-1.47)
<u>≥1% vs. <1% TST SaO₂<80%</u>				
Model 1: Crude model	1.58 (1.15-2.20)	1.54 (0.90-2.65)	2.46 (1.45-4.17)	0.99 (0.50-1.94)
Model 2a: Model 1 + MV	1.54 (1.09-2.16)	1.53 (0.88-2.68)	2.30 (1.35-3.92)	0.81 (0.37-1.78)
Model 2b: Model 1 + # high inflammatory markers	1.54 (1.11-2.14)	1.48 (0.86-2.55)	2.45 (1.44-4.14)	0.94 (0.48-1.86)
Model 3: Model 1 + MV* + # high inflammatory markers	1.57 (1.11-2.22)	1.62 (0.93-2.84)	2.31 (1.36-3.94)	0.82 (0.38-1.81)
<u>TST <5 vs. 5-8</u>				
Model 1: Crude model	1.28 (1.02-1.62)	1.25 (0.85-1.84)	0.98 (0.61-1.58)	1.56 (1.09-2.24)
Model 2a: Model 1 + MV	1.17 (0.92-1.48)	1.19 (0.80-1.77)	0.94 (0.58-1.53)	1.35 (0.92-1.97)
Model 2b: Model 1 + # high inflammatory markers	1.20 (0.95-1.51)	1.15 (0.78-1.69)	0.97 (0.60-1.56)	1.45 (1.01-2.08)
Model 3: Model 1 + MV* + # high inflammatory markers	1.12 (0.89-1.42)	1.12 (0.76-1.67)	0.93 (0.58-1.52)	1.28 (0.87-1.88)
<u>TST >8 vs. 5-8</u>				
Model 1: Crude model	1.02 (0.76-1.37)	0.93 (0.55-1.55)	0.59 (0.29-1.20)	1.46 (0.96-2.21)
Model 2a: Model 1 + MV	0.94 (0.69-1.27)	0.92 (0.55-1.55)	0.57 (0.27-1.17)	1.29 (0.83-2.00)
Model 2b: Model 1 + # high inflammatory markers	1.03 (0.77-1.38)	0.94 (0.56-1.57)	0.59 (0.29-1.20)	1.47 (0.97-2.22)
Model 3: Model 1 + MV* + # high inflammatory markers	0.83 (0.71-1.31)	0.95 (0.56-1.61)	0.57 (0.28-1.18)	1.32 (0.85-2.05)
<u>Sleep latency ≥60 vs. <60 min</u>				
Model 1: Crude model	1.25 (0.99-1.58)	1.24 (0.84-1.84)	1.23 (0.78-1.93)	1.28 (0.88-1.87)
Model 2a: Model 1 + MV	1.13 (0.89-1.44)	1.14 (0.76-1.71)	1.22 (0.77-1.94)	1.06 (0.71-1.58)
Model 2b: Model 1 + # high inflammatory markers	1.19 (0.94-1.50)	1.15 (0.78-1.70)	1.22 (0.77-1.92)	1.20 (0.82-1.75)
Model 3: Model 1 + MV* + # high inflammatory markers	1.12 (0.88-1.42)	1.13 (0.75-1.69)	1.25 (0.79-1.98)	1.04 (0.70-1.56)